Clinical trials: Hepatitis C, completed
Mental Disorders, Drug Addiction
Treatment of Hepatitis C in Psychiatric Patients
Psychiatric disorders or drug addiction are often regarded as contraindications against the use of Interferon-alpha in patients with chronic hepatitis C.
- Trial name
- NCT00751426
- Where
- Germany
- Volunteers
- 81 people
- Sponsor
- Charite University, Berlin, Germany
Hepatitis C
Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment
The purpose of this study is to test the potential antiviral efficacy of triple-combination therapy with Peginterferon α-2b + ribavirin + boceprevir (PRB) in patients with HCV genotype 3 who previously failed Peginterferon α +…
- Trial name
- LeeG3 (NCT01585584)
- Testing
- Boceprevir
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- University of Calgary
Chronic Hepatitis C Viral Infection
Do Low High Density Lipoprotein (HDL) Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection?
The working hypothesis is that the low HDL serum level predict favorable response to anti viral treatment in chronic HCV (genotype 1) viral infection. This might be used to improve the rate of sustained virologic response.
- Trial name
- NCT01159613
- Testing
- Responders, Non Responders
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Ziv Hospital
Hepatitis C
Surveillance and Treatment of Prisoners With Hepatitis C
The purpose of the study is to assess how feasible it is to treat and prevent the transmission of Hepatitis C in the prison setting to achieve substantial reductions in the incidence and prevalence of Hepatitis C.
- Trial name
- SToP-C (NCT02064049)
- Testing
- Sofosbuvir/velpatasvir
- Where
- 4 sites in Australia
- Volunteers
- 3,692 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Hepatitis C, Chronic
Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)
The purpose of this study is to evaluate the pharmacokinetics (PK) and safety and tolerability of single-dose administration of IDX719 in participants with normal hepatic function and participants with varying degrees of hepatic…
- Trial name
- NCT01919125
- Testing
- IDX719
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
A Retrospective Study of Real World Treatment Outcomes of Patients With Chronic Hepatitis C
This retrospective, observational study will assess the real world treatment out comes in the management of patients with chronic hepatitis C.
- Trial name
- NCT01705717
- Where
- Thailand
- Volunteers
- 49 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C Virus
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
The purpose of this study is to evaluate the efficacy of 6 or 8 weeks of treatment regimen containing simeprevir (SMV), daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naive (not having received treatment with any approved or…
- Trial name
- ACCORDION-1 (NCT02349048)
- Testing
- Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg
- Where
- 8 sites in United States, Canada
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
HIV, Hepatitis C
Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection
HIV infection exerts a negative impact on the course of HCV infection. Co-infected individuals progress more rapidly to liver fibrosis, cirrhosis and ESLD compared to those infected with HCV alone.
- Conditions
- HIV, Hepatitis C, Liver Fibrosis
- Trial name
- NCT01231685
- Testing
- Raltegravir, Ritonavir-boosted protease inhibitor
- Where
- 3 sites in Canada
- Volunteers
- 9 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
HIV, Hepatitis C
Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers
The investigator believes simeprevir concentrations are unchanged when administered in combination with dolutegravir relative to administration alone.
- Trial name
- NCT02404805
- Testing
- dolutegravir, simeprevir
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Hepatitis C, Chronic
A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C
This 2 arm open-label study will assess the safety and tolerability of combination treatment with Peginterferon alfa (Pegasys) and Ribavirin (Copegus) in patients with chronic hepatitis C.
- Trial name
- NCT00940420
- Testing
- Copegus (ribavirin), peginterferon alfa-2a [Pegasys]
- Where
- 20 sites in Israel
- Volunteers
- 2,695 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Hepatitis C
Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV
In this study, researchers from UCLA and Friends Community Center will work together in designing a program to assist young homeless stimulant-using gay and bisexual homeless men to complete the hepatitis vaccine and in reducing…
- Conditions
- Hepatitis B, Hepatitis C, HIV, HIV Infections
- Trial name
- HBV (NCT00926146)
- Testing
- NCMIT, SCMIT
- Where
- United States
- Volunteers
- 451 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
ESRD, Hepatitis C
Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR
It is well recognized that a subset of patients who contracts Hepatitis C virus (HCV) spontaneously clears the virus. Such individuals are anti-HCV antibody positive, yet HCV RNA PCR negative in the blood.
- Trial name
- NCT02669966
- Testing
- Kidney transplantation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Florida
Hepatitis C
Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients
To evaluate the antiviral activity of 3 days of BZF961. To determine safety and tolerability of BZF961 in HCV patients. To evaluate pharmacokinetics of BZF961 in HCV patients.
- Trial name
- CBZF961X2201 (NCT01825980)
- Testing
- BZF961, Ritonavir
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis C (Disorder)
Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs
Recently,surprisingly and unexpectedly increased aggressiveness and high rates of HCC recurrence (28%(16/58) and 29%(17/59), respectively) have been reported in patients who cleared HCV with DAAs after achieving a complete…
- Trial name
- NCT03063723
- Testing
- Ledipasvir-Sofosbuvir, Daclatasvir-Sofosbuvir
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis C, Chronic
The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study
Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) offers a cure to those with chronic HCV infection. For marginalized communities, linkage to care services often aren't enough to overcome barriers to accessing the…
- Trial name
- NOW (NCT03987503)
- Testing
- Epclusa (SOF/VEL), Standard of care, Fibroscan® 430 Mini Plus
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Chronic Hepatitis C
Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)
The primary objective of this study is to determine the safe and effective dose range of boceprevir (SCH 503034) in combination with PEG-Intron in adult subjects who have chronic hepatitis C without cirrhosis, and who have failed…
- Trial name
- NCT00160251
- Testing
- Boceprevir (BOC), PegIntron (PEG), Ribavirin (RBV)
- Volunteers
- 357 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Heart Transplant
Expanding the Pool in Orthotopic Heart Transplantation
This is an open-label, pilot trial to test the safety and efficacy of transplantation of hearts from HCV seropositive non-viremic (HCV Ab+/NAT-) and HCV seropositive viremic (HCV Ab+/NAT+) donors to HCV seronegative recipients on…
- Conditions
- Hepatitis C, Heart Transplant, Cardiac Transplant
- Trial name
- NCT03222531
- Testing
- sofosbuvir/velpatasvir
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mary E. Keebler, MD
Hepatitis C, Chronic
Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)
This is a controlled, randomized, parallel-groups, open-label, multinational study designed to evaluate the efficacy and safety of PEG-Intron® (pegylated interferon alfa-2b) plus Rebetol® (ribavirin) in subjects with chronic…
- Trial name
- NCT00265395
- Testing
- Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®), Combination of pegylated interferon alfa-2b and ribavirin
- Volunteers
- 1,428 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis, Hepatitis C
An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients
The purpose of the study is to demonstrate the noninferiority of Algeron in combination with ribavirin compared to PegIntron in combination with ribavirin in treatment of chronic hepatitis C in Human Immunodeficiency Virus-1…
- Conditions
- Hepatitis, Hepatitis C, Hepatitis C/ Human Immunodeficiency Virus Coinfection
- Trial name
- NCT02103439
- Testing
- Algeron, PegIntron
- Where
- 6 sites in Russia
- Volunteers
- 140 people
- Sponsor
- Biocad
Hepatitis C, Chronic
A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C
This 4-arm study will compare the efficacy and safety of PEGASYS induction and maintenance dosing, versus standard fixed dosing in combination with Copegus, and the efficacy and safety of higher dose versus standard dose Copegus…
- Trial name
- NCT00394277
- Testing
- peginterferon alfa-2a, Ribavirin
- Where
- 184 sites in United States, Belgium and 13 more
- Volunteers
- 1,175 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.